Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841143 | 0.85 | MAPK11 (0.49) | MAPK11EGFRMAPK9MAPK14MAPK13 | |
| SCHEMBL4027443 | 0.76 | BRAF (0.49) | MAPK11MAPK14GRIA1HDAC2HDAC1 | |
| SCHEMBL14840744 | 0.76 | MAPK14 (0.47) | MAPK11EGFRMAPK9MAPK14MAPK13 | |
| SCHEMBL16512720 | 0.73 | GPR119 (0.42) | GPR119HDAC2HDAC1NAMPT | |
| SCHEMBL25458288 | 0.73 | GPR119 (0.50) | GPR119NAMPT | |
| SCHEMBL3266179 | 0.73 | RORC (0.51) | HDAC2HDAC1 | |
| SCHEMBL4024940 | 0.71 | MAPK14 (0.45) | MAPK11MAPK14MAPK13GCGRMAPK12 | |
| SCHEMBL4584849 | 0.71 | CSNK1A1 (0.60) | MAPK11MAPK9GPR119MAPK14MAPK13 | |
| SCHEMBL4025352 | 0.71 | CSNK1A1 (0.60) | MAPK11MAPK9GPR119MAPK14MAPK13 | |
| SCHEMBL1239091 | 0.69 | RORC (0.48) | HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006268-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006268-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | MAPK11 3172/4885EGFR 4249/4885MAPK9 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.